Nexalin Technology (NXL) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NXL Nexalin Technology

Watchlist

2.9700
-0.2200-6.90%

Close Jan 8 16:00 ET

2.9200
-0.0500-1.68%

Post 20:01 ET

39.51MMarket Cap-4.57P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Nexalin Technology Completes Phase 1of Its Innovative Virtual Clinic
GlobeNewswireDec 23, 2024 10:00 ET
Nexalin Files for Potential Stock Sale by Maxim Partners
MT NewswiresDec 20, 2024 14:14 ET
Nexalin Technology Cut to Hold From Buy by Maxim Group
Dow JonesDec 5, 2024 15:21 ET · Ratings
Nexalin Technology Analyst Ratings
BenzingaDec 5, 2024 15:10 ET · Ratings
Maxim Group Downgrades Nexalin Technology(NXL.US) to Hold Rating
Moomoo NewsDec 5, 2024 12:35 ET · Ratings
New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
GlobeNewswireNov 26, 2024 10:00 ET

Comments

Stock_Drift

Dec 23, 2024 09:22

$Nexalin Technology (NXL.US)$

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...